Beloved Australian actor, Magda Szubanski, has revealed she's been diagnosed with a "very rare, very aggressive, very serious" blood cancer called mantle cell lymphoma. In a post on social media on ...

• BTK inhibitors work by targeting and blocking the BTK enzyme, which is crucial for the survival and growth of cancerous B-cells in mantle cell lymphoma (MCL). This cuts off the cancer cell’s support ...

Real-world data show zanubrutinib cuts atrial fibrillation, major bleeding, and mortality versus ibrutinib in B‑cell cancers—guiding safer BTK inhibitor choices. Mosunetuzumab, a bispecific, plus ...

Translocations are chromosomal “cut and paste” errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but ...

BeOne Medicines Ltd. ONC shares are trading lower on Tuesday as the company shared topline results from its Phase 3 MANGROVE ...

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said. Treatment with CAR-T cell therapy Breyanzi ...

Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma that affects B cells, a type of white blood cell (lymphocyte) that helps fight infections. In people with MCL, B cells grow and ...

Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent ...

The latest approval of lisocabtagene maraleucel (liso-cel) in mantle cell lymphoma provides another treatment option and continues the tremendous advances in treatment for patients, said Christopher ...

Researchers at Karolinska Institutet have discovered that mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer, is already highly diverse at the time of diagnosis and continues to ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating ...